BIO Releases its Principles on Clinical Trial Data Sharing
With the joint release and agreement of the PhRMA and EFPIA on those organizations clinical trial data sharing and transparency principles, BIO has releases its own Principles on Clinical Trial Data Sharing.
With the joint release and agreement of the PhRMA and EFPIA on those organizations clinical trial data sharing and transparency principles, BIO has releases its own Principles on Clinical Trial Data Sharing. Similar to the pharmaceutical members companies of PhRMA and EFPIA, BIO companies agree to the following:
1. Registering Clinical Trials: BIO member companies will register all company sponsored clinical trials conducted in patients in an appropriate public registry, such as ClinicalTrials.gov or the European Clinical Trials Database (EudraCT).
2. Summarizing the Results of Clinical Trials: BIO member companies will post technical summary results in a clinical trials database, with caveats.
3. Publishing Clinical Trials: BIO member companies will submit for publication in the scientific literature, or otherwise make available to the scientific community.
4. Providing Factual Summaries of Clinical Trials to Research Participants.
5. Responsibly Sharing Additional Clinical Trial Data. The difference here is that BIO member companies will develop and make public its procedures for this process, unlike the PhRMA/EFPIA principles, whose members companies agree to have requests reviewed by a separate scientific review board not employed by the company.
Read the full release here.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
